http://www.amgennews.com/index.php en pmannle@amgen.com Copyright 2012 2012-01-26T22:31:00+00:00 http://www.amgennews.com/index.php/2008NewsService/treatment_with_prolia_denosumab_associated_with_significantly_greater_adher/ http://www.amgennews.com/index.php/2008NewsService/treatment_with_prolia_denosumab_associated_with_significantly_greater_adher/#When:22:22:00Z New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Press Releases, Product News 2011-03-23T22:22:00+00:00 http://www.amgennews.com/index.php/2008NewsService/prolia_denosumab_open_label_extension_trial_showed_continued_increase_in_bo/ http://www.amgennews.com/index.php/2008NewsService/prolia_denosumab_open_label_extension_trial_showed_continued_increase_in_bo/#When:21:44:00Z THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth years of consecutive Prolia treatment. Press Releases, Product News 2011-03-23T21:44:00+00:00 http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improves_progressi/ http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improves_progressi/#When:03:30:00Z THOUSAND OAKS, Calif. – Sept 24, 2009 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘203’ trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 10LBA). Press Releases, Product News, Pipeline News 2009-09-24T03:30:00+00:00 http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improves_progressi/ http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improves_progressi/#When:00:32:01Z THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA). Press Releases, Product News, Pipeline News 2009-09-22T00:32:01+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_pivotal_data_from_four_phase_3_studies_at_the_ecco_15_esmo/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_pivotal_data_from_four_phase_3_studies_at_the_ecco_15_esmo/#When:15:45:00Z Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented: Amgen announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.  Press Releases, Product News 2009-09-16T15:45:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_top_line_results_of_trial_to_reduce_cardiovascular_events_w/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_top_line_results_of_trial_to_reduce_cardiovascular_events_w/#When:20:36:00Z THOUSAND OAKS, Calif.—Aug. 25—Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type 2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp(R) (darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. Press Releases, Product News 2009-08-25T20:36:00+00:00 http://www.amgennews.com/index.php/2008NewsService/vectibixr_significantly_improved_progression_free_survival_in_second_line_t/ http://www.amgennews.com/index.php/2008NewsService/vectibixr_significantly_improved_progression_free_survival_in_second_line_t/#When:14:13:01Z Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show Progression-Free Survival Advantage in KRAS Wild-Type Population THOUSAND OAKS, Calif. – Aug. 17 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival. Press Releases, Product News 2009-08-17T14:13:01+00:00 http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improved_progressi/ http://www.amgennews.com/index.php/2008NewsService/vectibixr_in_combination_with_chemotherapy_significantly_improved_progressi/#When:13:15:00Z Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population Phase 3 Results Reinforce Importance of KRAS Testing THOUSAND OAKS, Calif. – Aug. 6 – Amgen (Nasdaq: AMGN) today announced that Vectibix (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). Press Releases, Product News 2009-08-06T13:15:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_kras_safety_update_to_us_prescribing_information_for_vectib/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_kras_safety_update_to_us_prescribing_information_for_vectib/#When:16:26:00Z Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr Antibody Monotherapy in Metastatic Colorectal Cancer Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in Combination Therapy Expected In Third Quarter 2009  THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab). This decision follows the FDA’s December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFr antibody was discussed. Press Releases, Product News 2009-07-17T16:26:00+00:00 http://www.amgennews.com/index.php/2008NewsService/new_study_shows_nplater_significantly_reduces_splenectomy_rate_and_treatmen/ http://www.amgennews.com/index.php/2008NewsService/new_study_shows_nplater_significantly_reduces_splenectomy_rate_and_treatmen/#When:09:42:00Z BERLIN – June 7 – Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672). Press Releases, Product News 2009-06-08T09:42:00+00:00